Agents for combating circulatory illnesses and their use

Claim 2

A pharmaceutical composition containing as an active ingredient an amount effective for treating cardiac insufficiencies, of a compound of the formula ##STR112## in which X represents a bridge member having 2 or 3 carbon atoms, which is optionally substituted by 1 or 2 C 1 -C 4 alkyl radicals R 1 represents a hydrogen atom or a C 1 -C 18 alkyl or alkenyl radical, the alkenyl radical containing 1 or 2 double bonds, a phenyl or a benzyl radical, both optionally being substituted by a CF 3 group, a fluorine or a nitro group, R 4 represents a hydrogen atom, a nitro group, an acylamino group containing an acyl radical, the acyl radical being derived from a C 1 -C 12 aliphatic carboxylic acid or a phenyl carboxylic acid, which is optionally substituted in the phenyl radical by OH, halogen C 1 -C 4 alkyl, C 1 -C 4 alkoxy, nitro or amino, a sulfonylamino group containing a sulfonyl radical, the sulfonyl radical being derived from an C 1 -C 6 aliphatic sulfonic acid or a phenyl sulfonic acid, the phenyl radical of which can be substituted by NO 2 , amino, acetamido, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen or CF 3 , an aminosulfonic group of (1) ammonium, (2) a C 1 -C 12 primary or secondary amine, (3) a heterocyclic amine selected from the group consisting of piperidine, pyrrolidine, morpholine and piperazine or (4) aniline or an aniline which is optionally substituted by halogen, C 1 -C 4 alkyl or C 1 -C 4 alkoxy, optionally being substituted by halogen, C 1 -C 4 --alkyl or C 1 -C 4 --alkoxy, trifluoromethyl or trifluoromethoxy.

Claim 3

A pharmaceutical composition containing as an active ingredient an amount effective for treating cardiac insufficiencies, of a compound of the formula ##STR113## in which R 1 is hydrogen, alkyl, alkenyl, or alkynyl, each with up to 18 atoms of carbon, aralkyl, C 1 -C 4 --alkyl--N--(C 1 -C 4 --alkyl) 2 , C 1 -C 4 --alkyl-phenyl(Cl) x , wherein x is 1 or 2, phenyl optionally substituted with 1 to 3 identical or different substituents selected from NO 2 , halogen, or CF 3 , R 2 is C 1 -C 6 --alkyl and alkenyl; phenyl; C 1 -C 6 --alkoxy; phenoxy; C 1 -C 6 --alkylthio; phenylthio; C 1 -C 6 --alkylsulfonyl; phenylsulfonyl; acetyl; benzoyl; trifluoromethyl; trifluoromethoxy; trifluoromethylthio; hydroxymethyl, aminomethyl, C 1 -C 6 --alkylcarbonyloxymethyl, C 1 -C 4 --alkylcarbonylaminomethyl, phenethyl; C 1 -C 4 --alkylcarbonyloxy; C 1 -C 4 --mono- and dialkylamino; acylamino, wherein the acyl radical is derived from aliphatic carboxylic acid with 1 to 12 carbon atoms; C 1 -C 5 --alkoxycarbonylamino; a urea radical, wherein the second nitrogen atom is substituted with C 1 -C 12 --alkyl, or phenyl, or sulfonylamino, wherein the sulfonyl radical is derived from aliphatic sulfonic acids with 1 to 6 carbon atoms or from phenylsulfonic acids with a phenyl radical that can be substituted with NO 2 , amino, acetamido, C 1 -C 4 --alkyl, C 1 -C 4 --alkoxy, halogen, or CF 3 ; or carbonamido of ammonia, of C 1 -C 12 aliphatic primary or secondary amines, of heterocyclic amines selected from the group consisting of piperidine, pyrrolidine, morpholine, and piperazine, of aniline or an aniline, which is substituted with halogen C 1 -C 4 --alkyl, or C 1 -C 4 --alkoxy; a sulfonic-acid group, a sulfonamido of NH 3 , C 1 -C 12 primary or secondary amines, of piperidine, piperazine, or morpholine, F, Cl, or Br, and R 3 represents hydrogen, C 1 -C 4 --alkyl, phenyl, or benzyl as well as their pharmaceutically compatible salts with inorganic or organic acids.

Claim 4

A pharmaceutical composition containing as an active ingredient an amount effective for treating cardiac insufficiencies, of a compound of the formula ##STR113## in which R 1 is hydrogen, alkyl, alkenyl, or alkynyl, each with up to 18 atoms of carbon, aralkyl, C 1 -C 4 --alkyl--N--(C 1 -C 4 --alkyl) 2 , C 1 -C 4 --alkyl-phenyl(Cl) x , wherein x is 1 or 2, phenyl optionally substituted with 1 to 3 identical or different substituents selected from NO 2 , halogen, or CF 3 , R 2 is C 1 -C 6 --alkyl and alkenyl; phenyl; C 1 -C 6 --alkoxy; phenoxy; C 1 -C 6 --alkylthio; phenylthio; C 1 -C 6 --alkylsulfonyl; phenylsulfonyl; acetyl; benzoyl; trifluoromethyl; trifluoromethoxy; trifluoromethylthio; hydroxymethyl, aminomethyl, C 1 -C 6 --alkylcarbonyloxymethyl, C 1 -C 4 --alkylcarbonylaminomethyl, phenethyl; C 1 -C 4 --alkylcarbonyloxy; C 1 -C 4 --mono- and dialkylamino; acylamino, wherein the acyl radical is derived from aliphatic carboxylic acid with 1 to 12 carbon atoms; C 1 -C 5 --alkoxycarbonylamino; a urea radical, wherein the second nitrogen atom is substituted with C 1 -C 12 --alkyl, or phenyl, or sulfonylamino, wherein the sulfonyl radical is derived from aliphatic sulfonic acids with 1 to 6 carbon atoms or from phenylsulfonic acids with a phenyl radical that can be substituted with NO 2 , amino, acetamido, C 1 -C 4 --alkyl, C 1 -C 4 --alkoxy, halogen, or CF 3 ; or carbonamido of ammonia, of C 1 -C 12 aliphatic primary or secondary amines, of heterocyclic amines selected from the group consisting of piperidine, pyrrolidine, morpholine, and piperazine, of aniline or an aniline, which is substituted with halogen C 1 -C 4 --alkyl, or C 1 -C 4 --alkoxy; a sulfonic-acid group, a sulfonamido of NH 3 , C 1 -C 12 primary or secondary amines, of piperidine, piperazine, or morpholine, F, Cl, or Br, and R 3 represents hydrogen, C 1 -C 4 --alkyl, phenyl, or benzyl as well as their pharmaceutically compatible salts with inorganic or organic acids.

Claim 5

A compound of the formula ##STR114## in which R 1 is hydrogen, alkyl, alkenyl, or alkynyl, each with up to 18 atoms of carbon, aralkyl, C 1 -C 4 --alkyl--N--(C 1 -C 4 --alkyl) 2 , C 1 -C 4 --alkyl-phenyl(cl) x , wherein x is 1 or 2, phenyl optionally substituted with 1 to 3 identical or different substituents selected from NO 2 , halogen, or CF 3 , R 2 is C 1 -C 6 --alkyl and alkenyl; phenyl; C 1 -C 6 --alkoxy; phenoxy; C 1 -C 6 --alkylthio, phenylthio; C 1 -C 6 --alkylsulfonyl; phenylsulfonyl; acetyl; benzoyl; trifluoromethyl; trifluoromethoxy; trifluoromethylthio; hydroxymethyl, aminomethyl, C 1 -C 6 --alkylcarbonyloxymethyl, C 1 -C 4 --alkylcarbonylaminomethyl, phenethyl, C 1 -C 4 --alkylcarbonyloxy; C 1 -C 4 --mono- and dialkylamino; acylamino, wherein the acyl radical is derived from aliphatic carboxylic acid with 1 to 12 carbon atoms; C 1 -C 4 --alkoxycarbonylamino; a urea radical, wherein the second nitrogen atom is substituted with C 1 -C 12 --alkyl, or phenyl, or sulfonylamino, wherein the sulfonyl radical is derived from aliphatic sulfonic acids with 1 to 6 carton atoms or from phenylsulfonic acids with a phenyl radical that can be substituted with NO 2 , amino, acetamido, C 1 -C 4 --alkyl, C 1 -C 4 --alkoxy, halogen, or CF 3 ; or carbonamido of ammonia, of C 1 -C 12 aliphatic primary or secondary amines, of heterocyclic amines selected from the group consisting of piperidine, pyrrolidine, morpholine, piperazine, of aromatic amines, which are unsubstituted or substituted with halogen C 1 -C 4 --alkyl, or C 1 -C 4 --alkoxy; a sulfonic-acid group, a sulfonamido of NH 3 , C 1 -C 12 primary or secondary amines, of piperidine, piperazine, or morpholine, F, Cl, or Br, and R 3 represents hydrogen, C 1 -C 4 --alkyl, phenyl, or benzyl as well as their pharmaceutically compatible salts with inorganic or organic acids.

Claim 6

A compound of the formula ##STR114## in which R 1 is hydrogen, alkyl, alkenyl, or alkynyl, each with up to 18 atoms of carbon, aralkyl, C 1 -C 4 --alkyl--N--(C 1 -C 4 --alkyl) 2 , C 1 -C 4 --alkyl-phenyl(cl) x , wherein x is 1 or 2, phenyl optionally substituted with 1 to 3 identical or different substituents selected from NO 2 , halogen, or CF 3 , R 2 is C 1 -C 6 --alkyl and alkenyl; phenyl; C 1 -C 6 --alkoxy; phenoxy; C 1 -C 6 --alkylthio, phenylthio; C 1 -C 6 --alkylsulfonyl; phenylsulfonyl; acetyl; benzoyl; trifluoromethyl; trifluoromethoxy; trifluoromethylthio; hydroxymethyl, aminomethyl, C 1 -C 6 --alkylcarbonyloxymethyl, C 1 -C 4 --alkylcarbonylaminomethyl, phenethyl, C 1 -C 4 --alkylcarbonyloxy; C 1 -C 4 --mono- and dialkylamino; acylamino, wherein the acyl radical is derived from aliphatic carboxylic acid with 1 to 12 carbon atoms; C 1 -C 4 --alkoxycarbonylamino; a urea radical, wherein the second nitrogen atom is substituted with C 1 -C 12 --alkyl, or phenyl, or sulfonylamino, wherein the sulfonyl radical is derived from aliphatic sulfonic acids with 1 to 6 carton atoms or from phenylsulfonic acids with a phenyl radical that can be substituted with NO 2 , amino, acetamido, C 1 -C 4 --alkyl, C 1 -C 4 --alkoxy, halogen, or CF 3 ; or carbonamido of ammonia, of C 1 -C 12 aliphatic primary or secondary amines, of heterocyclic amines selected from the group consisting of piperidine, pyrrolidine, morpholine, piperazine, of aromatic amines, which are unsubstituted or substituted with halogen C 1 -C 4 --alkyl, or C 1 -C 4 --alkoxy; a sulfonic-acid group, a sulfonamido of NH 3 , C 1 -C 12 primary or secondary amines, of piperidine, piperazine, or morpholine, F, Cl, or Br, and R 3 represents hydrogen, C 1 -C 4 --alkyl, phenyl, or benzyl as well as their pharmaceutically compatible salts with inorganic or organic acids.

Claim 7

A composition according to claim 1 in which the active ingredient is 9-Trifluoromethyl-5-oxo-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 8

A composition according to claim 1 in which the active ingredient is 9-Isovaleroylamino-5-oxo-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 9

A composition according to claim 1 in which the active ingredient is 9-(4-Morpholinylsulphonyl)-5-oxo-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 10

A composition according to claim 1 in which the active ingredient is 9-Trifluoromethyl-5-oxo-(3- or 2-methyl)-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 11

A composition according to claim 1 in which the active ingredient is 10-Nitro-6-oxo-7-allyl-2,3,4,5,6,7-hexahydropyrimido-[1,2-c]-quinazoline.

Claim 12

A pharmaceutical composition of claims 1 in the form of a sterile or physiologically isotonic aqueous solution.

Claim 13

A composition according to claims 1, containing from 0.5 to 95% of the said active ingredient, by weight.

Claim 14

A medicament in dosage unit form comprising an amount effective for treating cardiac insufficiencies, of a compound as defined in claims 1 either alone or in admixture with a diluent.

Claim 15

A medicament of claim 1 in the form of tablets, pills, dragees, capsules, ampoules, or suppositories comprising a compound as defined in claim 1 either alone or in admixture with a diluent.

Claim 16

A method of combating circulatory illnesses in warm-blooded animals which comprises administering to the animals a compound effective for treating cardiac insufficiencies as defined in claim 1 either alone or in admixture with a diluent or in the form of a medicament.

Claim 17

A method according to claim 13 in which the active compound is administered orally in an amount of 0.1 to 100 mg per kg body weight per day.

Claim 18

A method according to claim 14 in which the active compound is administered orally in an amount of 1.0 to 50 mg/kg of body weight per day.

Claim 19

A pharmaceutical composition of claim 1 containing, as an active ingredient, an amount of active compound effective for treating congestive heart failure.

Claim 20

A method of treating congestive heart failure in warm-blooded animals which comprises administering to the animals a compound effective for treating congestive heart failure as defined in claim 1 either alone or in admixture with a diluent or in the form of a medicament.

Claim 21

A compound of claim 3 which is 9-Trifluoromethyl-5-oxo-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 22

A compound of claim 3 which is 9-Isovaleroylamino-5-oxo-2,3,5,6-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 23

A compound of claim 3 which is 9-(4-Morpholinysulphonyl)-5-oxo-2,3,5,6,-tetrahydroimidazo-[1,2-c]-quinazoline.

Claim 24

A compound of claim 3 which is 9-Trifluoromethyl-5-oxo(3- or 2-methyl)-2,3,5,6,-tetrahydroimidazo-[1,2-c]-quinazoline.